home / stock / ngenf / ngenf quote
Last: | $1.68 |
---|---|
Change Percent: | 5.0% |
Open: | $1.63 |
Close: | $1.60 |
High: | $1.71 |
Low: | $1.63 |
Volume: | 50,266 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.68 | $1.63 | $1.6 | $1.71 | $1.63 | 50,266 | 05-03-2024 |
$1.6 | $1.49 | $1.6 | $1.61 | $1.49 | 92,409 | 05-02-2024 |
$1.48 | $1.53 | $1.48 | $1.5315 | $1.48 | 14,535 | 05-01-2024 |
$1.52 | $1.5 | $1.52 | $1.58 | $1.49 | 43,270 | 04-30-2024 |
$1.5 | $1.55 | $1.5 | $1.57 | $1.5 | 43,385 | 04-29-2024 |
$1.55 | $1.5025 | $1.55 | $1.58 | $1.5025 | 50,284 | 04-26-2024 |
$1.5 | $1.52 | $1.5 | $1.56 | $1.47 | 51,535 | 04-25-2024 |
$1.53 | $1.53 | $1.53 | $1.61 | $1.5 | 59,050 | 04-24-2024 |
$1.53 | $1.556 | $1.53 | $1.63 | $1.53 | 20,509 | 04-23-2024 |
$1.57 | $1.636 | $1.57 | $1.636 | $1.54 | 30,114 | 04-22-2024 |
$1.59 | $1.5 | $1.59 | $1.625 | $1.455 | 63,046 | 04-19-2024 |
$1.45 | $1.45 | $1.45 | $1.47 | $1.4 | 62,580 | 04-18-2024 |
$1.4315 | $1.49 | $1.4315 | $1.49 | $1.42 | 68,184 | 04-17-2024 |
$1.48 | $1.64 | $1.48 | $1.64 | $1.45 | 34,434 | 04-16-2024 |
$1.5 | $1.56 | $1.5 | $1.57 | $1.5 | 54,594 | 04-15-2024 |
$1.57 | $1.57 | $1.57 | $1.6 | $1.56 | 15,771 | 04-12-2024 |
$1.575 | $1.59 | $1.575 | $1.59 | $1.54 | 39,375 | 04-11-2024 |
$1.61 | $1.51 | $1.61 | $1.61 | $1.5 | 63,536 | 04-10-2024 |
$1.5415 | $1.61 | $1.5415 | $1.61 | $1.5415 | 32,027 | 04-09-2024 |
$1.61 | $1.58 | $1.61 | $1.66 | $1.58 | 27,558 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
NervGen Pharma Corp Company Name:
NGENF Stock Symbol:
OTCMKTS Market:
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged...
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NV...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (" NervGen " or the " Company ") is pleased to announce the closing of its previously ann...